Autopsy report · NCT04729296
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
Cause of deathStaffing, sites or logistics
“Withdrawn due to COVID-19 related clinical limitations”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Sponsor type
- US National Institutes of Health
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Golimumab; Placebo
- Participants
- 0
Trials that died the same way
- Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)
“Withdrawn \[COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform\]” - Lisdexamfetamine for Adults With Bulimia Nervosa
“Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.” - TDCS-Augmented Prolonged Exposure Therapy
“Study withdrawn due to delay in recruitment due to COVID-19; the PI also moved to a new institution.” - fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population
“Study terminated due to COVID-19 restrictions” - SKY vs. HEP in PTSD
“Terminated due to Covid-19 pandemic related restrictions”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.